Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the outcomes of different coronary artery bypass grafting techniques in women with heart disease. The trial compares multiple arterial grafting MAG to single arterial grafting SAG to see if using multiple arterial grafts improves major heart and brain-related events and quality of life. This international randomized clinical trial includes 2,300 women to assess differences in survival, stroke, heart attacks, repeat surgeries, and hospital readmissions, as well as physical and mental health. Participants will be randomly assigned to one of two groups. One group receives a single arterial graft using the left internal thoracic artery plus additional venous grafts. The other group receives multiple arterial grafts, including the left internal thoracic artery and at least one other arterial graft such as the right internal thoracic artery or radial artery, with possible additional arterial grafts. The study uses the infrastructure of an existing trial and follows patients for at least 2.5 years after surgery. During the study, researchers collect data on major adverse cardiac and cerebrovascular events, along with quality of life measured by general and disease-specific questionnaires. Physical and mental health symptoms are also assessed. Follow-up includes tracking deaths, strokes, heart attacks, repeat procedures, and hospital stays. The trial aims to provide detailed information on outcomes and quality of life in women undergoing coronary bypass surgery over a long-term period.
Actively Recruiting
This research aims to improve care for people with severe asthma by collecting detailed health and treatment information over five years. The study focuses on participants with severe asthma classified at GINA Step 4 uncontrolled or at GINA Step 5, aiming to understand treatment responses and disease progression. The Canadian cohort gathers data from seven sites to help develop better asthma treatments and care strategies. Participants will have their medical information collected through interviews and medical chart reviews at baseline and yearly follow-ups for five years. Data collected include demographics, medical history, asthma medications, test results such as blood work, lung function, allergen tests, and imaging. All data are anonymized and securely stored to protect participant privacy. During the study, researchers will track various measures such as blood eosinophil and IgE levels, exhaled nitric oxide, asthma control over the past month, medication use, asthma exacerbations, emergency visits, hospital admissions, and lung function tests. Participant confidentiality is maintained, and research records may be reviewed for monitoring. The study spans five years with annual visits to monitor health and treatment outcomes.
Actively Recruiting
Researchers are studying critically ill adult patients who have been on invasive mechanical ventilation for more than 48 hours and are ready to undergo a Spontaneous Breathing Trial SBT to assess readiness for extubation. The study aims to improve and standardize decision-making for extubation in intensive care units by evaluating the Extubation Advisor EA, a bedside decision support tool that combines clinician assessments with predictive analytics to better predict extubation success and failure. This pilot trial will assess the feasibility of using the EA tool and inform a future larger randomized controlled trial to enhance extubation care and outcomes. In this randomized, single-blind trial, patients in the intervention group undergo an EA assessment during their SBTs. The device records waveform data and patient information, then generates a report that helps respiratory therapists and physicians decide whether to proceed with extubation. Patients in the control group receive standard care, with SBTs directed by clinicians without EA assessments or reports. The trial will assess recruitment feasibility, adherence to the protocol, and resource use over about 12 months. Participants will be monitored with assessments including the generation and delivery of EA reports and collection of clinical outcomes until hospital discharge. Researchers will evaluate the trials success based on recruitment rates, consent and randomization rates, adherence to intervention protocols, crossover occurrences, and completeness of clinical data. They will also assess the usefulness of the EA reports and measure institutional costs and time needed to implement the device. The study duration per participant varies according to clinical care and hospital stay.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate how adding two new questions and pictures to the Psoriasis Epidemiology Screening Tool PEST affects the potential diagnosis of psoriatic arthritis PsA in adults with moderate-to-severe plaque psoriasis PsO in Canada. The study focuses on patients who may need biologic Disease-Modifying Antirheumatic Drugs bDMARDs treatment and seeks to improve early detection of PsA. The study is prospective and involves multiple centers. Participants will first complete a modified PEST screening questionnaire, called PESTpictures2, at their initial dermatologist visit. This version includes the original 5 questions, two additional questions about morning stiffness and nighttime pain, and pictures to help patients identify symptoms like swollen joints and fingernail changes. Those who screen positive will have a follow-up visit with a rheumatologist for a thorough PsA diagnosis. At the end of the study, a remote visit with the dermatologist will record the participants bDMARD treatment choice and status. Patients will be enrolled for up to 120 days. During the study, participants will complete questionnaires and undergo assessments by dermatologists and rheumatologists. Researchers will measure the accuracy of the modified screening tool in predicting PsA, patient experience with the questionnaire, and characteristics of those with positive or negative screening results. Safety and treatment decisions related to bDMARDs will also be monitored. The main outcome is the positive predictive value of the screening tool within about one year.
Actively Recruiting
This trial evaluates the safety and effectiveness of Volrustomig in women with high-risk locally advanced cervical cancer FIGO 2018 stage IIIA to IVA who have not shown disease progression after platinum-based concurrent chemoradiation therapy CCRT. It is a global, randomized, double-blind, placebo-controlled Phase III study designed to assess outcomes in this specific patient population. Participants are randomly assigned in equal numbers to receive either Volrustomig or a placebo via intravenous infusion. The study compares these two groups to explore the potential benefits and risks of Volrustomig as a treatment following CCRT in women with high-risk locally advanced cervical cancer. Women taking part in the study will undergo multiple assessments over up to approximately seven years. Researchers monitor progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, subsequent therapies, and safety. Additional evaluations include tumor progression, pharmacokinetics, immunogenicity, adverse events, and patient-reported symptoms and quality of life. Participants provide tumor samples and undergo regular health evaluations during this period.